A Physiologically Based Pharmacokinetic Model for Capreomycin
Authors:
- 1 February 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (2) , 926-934
Abstract
The emergence of multidrug-resistant tuberculosis (MDR-TB) has led to a renewed interest in the use of second-line antibiotic agents. Unfortunately, there are currently dearths of information, data, and computational models that can be used to help design rational regimens for administration of these drugs. To help fill this knowledge gap, an exploratory physiologically based pharmacokinetic (PBPK) model, supported by targeted experimental data, was developed to predict the absorption, distribution, metabolism, and excretion (ADME) of the second-line agent capreomycin, a cyclic peptide antibiotic often grouped with the aminoglycoside antibiotics. To account for interindividual variability, Bayesian inference and Monte Carlo methods were used for model calibration, validation, and testing. Along with the predictive PBPK model, the first for an antituberculosis agent, this study provides estimates of various key pharmacokinetic parameter distributions and supports a hypothesized mechanism for capreomycin transport into the kidney.Keywords
This publication has 49 references indexed in Scilit:
- Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations Principles, Methods, and Applications in the Pharmaceutical IndustryCPT: Pharmacometrics & Systems Pharmacology, 2013
- Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampinJournal of Theoretical Biology, 2011
- Treatment of Active Pulmonary Tuberculosis in Adults: Current Standards and Recent AdvancesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approachToxicology and Applied Pharmacology, 2009
- Computational Toxicology of Chloroform: Reverse Dosimetry Using Bayesian Inference, Markov Chain Monte Carlo Simulation, and Human Biomonitoring DataEnvironmental Health Perspectives, 2008
- Use of Markov Chain Monte Carlo Analysis with a Physiologically‐Based Pharmacokinetic Model of Methylmercury to Estimate Exposures in U.S. Women of Childbearing AgeRisk Analysis, 2007
- A Novel Strategy for Physiologically Based Predictions of Human PharmacokineticsClinical Pharmacokinetics, 2006
- Physiological Parameter Values for Physiologically Based Pharmacokinetic ModelsToxicology and Industrial Health, 1997
- Antibiotic penetration into lung tissues.Thorax, 1994
- Clinical Pharmacokinetics of the Antituberculosis DrugsClinical Pharmacokinetics, 1984